News and Comments

New Development in Amgen offer To Acquire Onyx

  Sunday, June 30, 2013

In a new development, Onyx (ONXX) confirmed Amgen’s offer in the same release that announced rejecting it. Indeed, Onyx has rejected Amgen’s unsolicited proposal that suggests acquiring Onyx’s outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions.  More...

ONYX TAKEOVER WAS EXPECTED

  Sunday, June 30, 2013

In November 2011 Prohost posted an article titled “Deal or no deal, time for a payoff” (click HERE to read the article). All that prophesized in that article about Onyx’ (ONXX) drugs and prospects has materialized and the final item, a takeover, seems to be on the verge of happening.   More...

Two Small Great Biotechs Underestimated by the Market

  Tuesday, June 25, 2013

Seattle Genetics’ (SGEN) and ImmunoGen’s (IMGN) conjugated monoclonal antibody therapeutics for cancer are increasingly validating their superior safety and efficacy over other cancer products that are used without the antibody drug conjugates (ADC).  More...

Why Amgen and Cytokinetics Agreement is Good News?

  Wednesday, June 12, 2013

NEWS WE WERE WAITING FOR More...


Recent Postings


Archive


Tags

Regeneron (REGN) Revlimid (lenolidamide) Onyx (ONXX) Sarepta (SRPT) Mirati Therapeutics (MRTX) Seattle Genetics (SGEN) Elan (ELN) Velcade (bortezomib) ISIS (ISIS) Ionis (IONS) Ariad (ARIA) Prosensa (RNA) ImmunoGen (IMGN) ADVENTRIX (ANX) Editas (EDIT) Illumina (ILMN) Valeant Pharmaceuticals International (VRX) Inovio (INO) Spike Therapeutics (ONCE) PTC Therapeutics (PTCT) Galena (GALE) Array Pharmaceuticals (ARRY) Bellicum (BLCM) GUARDIAN HEALTH Jazz Pharmaceuticals (JAZZ) OSI (OSIP) VANDA (VNDA) Ziofpharm (ZIOP) Sanofi-Aventis (SAN) ABBVIE (ABBV) Sanofi (SNA) Exelixis (EXEL) Auspex (ASPX) Global Cell Therapeutics (GBT) SUNESIS PHARMACEUTICALS (SNSS) Theravance Bio Pharma (TBPH) Xoma (XOMA) Anacor (ANAC) ACADIA (ACAD) JUNO (JUNO) SERES THERAPEUTICS (MCRB) Vitae Pharmaceuticals (VTAE) Human Genome Sciences (HGSI) Alnylam (ALNY) Merck (MRK) Agenus (AGEN KERYX (KERX) Advaxis (ADXS) Trastuzumab-DM1 GlaxoSmithKline (GSK) SYNTA (SNTA) Cytokinetics (CYTK) Amgen (AMGN) AstraZeneca (AZN) HALOZYME (HALO) Agenus (AGEN) KITE (KITE) MODERNA galapagos (GLPG) AERIE PHARMACEUTICALS BIOMARIN (BMRN) CompuGen (CGEN) Sangamo (SGMO) NANTKWEST (NK) Dendreon (DNDN) REGULUS (RGLS) ARCA (ABIO) AGOS (ARGS) INNOVIVA (INVA) Tysabri Benlysta (belimumab) Prolor Biotech (PBTH) Roche (ROCHE) Multiple Myeloma Biogen Idec (BIIB) RenenxBio (RGNX) Endometrial Cancer Intermune (ITMN) C4 Therapeutics TOKAI (TKAOI) Theravance (THRX) Idenix (IDIX) CEMPRA (CEMP) Pluristem (PSTI) Gilead (GILD) Alder Biopharmaceuticals (ALDR) Herceptin Sequenom (SQNM) Roche (RHHBY) Intercept (ICPT) Human Longevity (HLI) Genentech ARGOS (ARGS) Telaprevir Aimmune Therapeutics (AIMT) ZALTRAP™ NOVOCURE (NVCR) CRISPR Therapeutics (CRSP) Bristol-Myers Squibb (BMY) Anadys (ANDS) Dynavax (DVAX) Micromet (MITI) Incyte (INCY) NEKTAR (NKTR)) Biocryst (BCRX) Abbott Laboratories (ABT) Ridaforolimus Zerenex Intrexon (XON) Adaptimmune (ADAP) Vertex (VRTX) Rapamune IDERA (IDRA) Sanofi (SNY) Ocular Therapeutix (OCUL)